Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Vivoryon Therapeut (VVY) NPV

Sell:€4.35 Buy:€4.68 Change: €0.045 (1.01%)
Market closed |  Prices as at close on 25 September 2020 | Switch to live prices |
Change: €0.045 (1.01%)
Market closed |  Prices as at close on 25 September 2020 | Switch to live prices |
Change: €0.045 (1.01%)
Market closed |  Prices as at close on 25 September 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vivoryon Therapeutics AG, formerly Probiodrug AG, is a Germany-based biopharmaceutical company active in the biotechnology and medical research industry. The Company focuses on the development therapeutic products for the treatment of Alzheimer’s disease. It develops drugs to target toxic pyroglutamate-Abeta (pGlu-Abeta) via two modes of action, namely by inhibiting the production of pGlu-Abeta and by clearing existing pGlu-Abeta from the brain. The Company develops specific inhibitors for the enzyme Glutaminyl Cyclase (QC) helping in the creation of pGlu-Abeta and engineers a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Its product pipeline comprises PQ912 and PQ1565, small molecule QC inhibitors, as well as PBD-C06, a pGlu-Abeta specific monoclonal antibody.

Contact details

Weinbergweg 22
+49 (345) 5559900

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€88.79 million
Shares in issue:
19.98 million
Euronext Amsterdam

Key personnel

  • Erich Platzer
    Chairman of the Supervisory Board
  • Ulrich Dauer
    Chief Executive Officer, Member of the Management Board
  • Dinnies von der Osten
    Independent Vice Chairman of the Supervisory Board
  • Michael Schaeffer
    Member of the Management Board, Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.